Dr. John O'Toole, M.D., M.S.

Claim this profile

Cleveland Clinic

Studies Spondylolisthesis
Studies Synovial Cyst
3 reported clinical trials
3 drugs studied

Affiliated Hospitals

Image of trial facility.

Cleveland Clinic

Image of trial facility.

Rush University Medical Center: University Neurosurgery

Clinical Trials John O'Toole, M.D., M.S. is currently running

Image of trial facility.

Regional Anesthesia

for Back Surgery

Opioid overuse is a widespread public health crisis in the United States with increasing rates of addiction and overdose deaths from prescription opioids. Reducing the need for opiate analgesics in the post-operative setting has become a high priority in minimizing long-term opioid use in surgical patients. This study will serve to demonstrate the efficacy of the addition of regional analgesic techniques in reducing post-operative opioid requirements in patients undergoing common lumbar spinal surgical procedures.

Recruiting

2 awards

Phase 4

Image of trial facility.

Kidney Biopsy

for Acute and Chronic Kidney Conditions

Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Despite significant effort from industry and academia, development of pharmacologic therapies for AKI and CKD has been hampered by: Non-predictive animal models The inability to identify and prioritize human targets The limited availability of human kidney biopsy tissue A poor understanding of AKI and CKD heterogeneity Historically, AKI and CKD have been described as single, uniform diseases. However, growing consensus suggests that different disease pathways lead to different subgroups of AKI and CKD (AKIs and CKDs). Access to human kidney biopsy tissue is a critical first step to define disease heterogeneity and determine the precise molecular pathways that will facilitate identification of specific drug targets and ultimately enable individualized care for people with AKI and CKD. A number of research centers across the United States are collaborating to bring state-of-the-art technologies together to: * Ethically obtain and evaluate kidney biopsies from participants with AKI or CKD * Define disease subgroups * Create a kidney tissue atlas * Identify critical cells, pathways, and targets for novel therapies The KPMP is made up of three distinct, but highly interactive, activity groups: * Recruitment Sites: The recruitment sites (RS) are responsible for recruiting participants with AKI or CKD into the longitudinal study and performing the kidney biopsy. * Tissue Interrogation Sites: The tissue interrogation sites (TIS) are responsible for developing and using innovative technologies to analyze the biopsy tissue. * Central Hub: The central hub is responsible for aggregating, analyzing, and visualizing the generated data and providing scientific, infrastructure, and administrative support for the KPMP consortium.

Recruiting

1 award

N/A

10 criteria

More about John O'Toole, M.D., M.S.

Clinical Trial Related

8 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments John O'Toole, M.D., M.S. has experience with

  • Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution Plus Clonidine
  • Normal Saline
  • Kidney Biopsy

Breakdown of trials John O'Toole, M.D., M.S. has run

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does John O'Toole, M.D., M.S. specialize in?

Is John O'Toole, M.D., M.S. currently recruiting for clinical trials?

Are there any treatments that John O'Toole, M.D., M.S. has studied deeply?

What is the best way to schedule an appointment with John O'Toole, M.D., M.S.?

What is the office address of John O'Toole, M.D., M.S.?

Is there any support for travel costs?